Conference-Service.com offers, as part of our business activities, a directory of upcoming scientific and technical meetings. The calendar is published for the convenience of conference participants and we strive to support conference organisers who need to publish their upcoming events. Although great care is being taken to ensure the correctness of all entries, we cannot accept any liability that may arise from the presence, absence or incorrectness of any particular information on this website. Always check with the meeting organiser before making arrangements to participate in an event!
Meeting organisers can submit meetings free of charge for inclusion into the listing.
- The formation and maturation of blood cells
- Classification and epidemiology of hematological malignancies
- Presentations, diagnosis and staging
- Chemotherapy and irradiation
- Clinical trial issues
The meeting is named for Dr. Bruce A. Chabner, Allen Distinguished Investigator, Clinical Director, Emeritus at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states, “It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead.
The 5th Emirates Oncology Conference 2016 will host around academics, oncologists, allied health professionals and medical students from the region, in addition to speakers from the UAE, the USA, Europe, and across the Middle East. Thought leaders in various specialties within oncology will discuss the latest treatments and advances and help improve oncology treatment in the UAE and the wider region.
As a medical professional with special interest in oncology, it will be of great benefit for you to participate in our fourth annual conference. Here, you will learn more about the latest developments in oncology with a view to improving regional standards of diagnosis, treatment and care.
Aim: There is a wealth of information on diet and cancer – not all of it based on good scientific evidence. This study day will aim to look at popular areas of nutrition and cancer and untangle the myths from the evidence. It will focus on topics frequently raised by those with cancer.
In addition to the advanced knowledge and insight about the breast cancer diagnosis and treatment, the conference will lay stress on the importance of essential oncologic concept along with integrity of reconstructive surgery. In order to reduce the physical mutilation and improve quality of life, the individualization of oncoplastic surgery principle can be applied to breast cancer patient care. The worldwide list of expert includes the breast cancer experts of oncologic surgery, reconstructive surgery and multidisciplinary team are willing to share their latest findings and valued experience. We believe that it will be an extraordinary academic event with your honorable participation.
During the last decade, it has become unequivocally evident that tumor development is not a cell-autonomous process but rather depends on the intricate reciprocal interplay of mutant tumor cells with their local and distant environments. Composition and polarization of cells in the tumor microenvironment depends on genetic as well as environmental factors and is directly influenced by tumor therapy. Indeed, therapies that aim to shape the local immune milieu and consecutive signaling pathways in both stromal and tumor/stem cells address the complex pathophysiology of tumors more adequately and may therefore add substantial benefits for therapy. An absolute pre-requisite for such an endeavor is a comprehensive understanding of the exact molecular basis of the complex signaling networks in the tumor microenvironment that control the plasticity of both stromal and tumor cells, thereby shaping the complex cellular contexture, which ultimately forms a pro- or anti-tumorigenic milieu. Thus, this symposium aims to gather a comprehensive functional understanding of mediator-dependent cellular and molecular events that are responsible for the plasticity of both stromal and tumor/stem cells. It will bring together experts in cancer, stromal and immune cells to synthesize scientific knowledge about the phenomenon of cell plasticity within the tumor microenvironment, to define molecular and cellular pathways mediating plasticity and to propose approaches to interfere with cell plasticity for a new generation of effective therapeutic approaches in cancer and chronic injury. Importantly, it will bring together interdisciplinary groups of scientists or investigators who normally would not have an opportunity to meet (classical cancer biologists, tumor immunobiologists, stem cell experts and scientists working on stromal cells).
The European Molecular Biology Laboratory (EMBL) and Cancer Core Europe - a consortium of Europe's 6 leading Comprehensive Cancer Centers (Gustave Roussy Cancer Campus Grand Paris, France; Cambridge Cancer Centre, United Kingdom; Karolinska Institutet, Sweden; Netherlands Cancer Institute (NKI), Vall d’Hebron Institute of Oncology, Spain and the German Cancer Research Centre (DKFZ) with it's National Center for Tumour Diseases (NCT) Heidelberg) - are proud to join forces to host the first EMBL-Cancer Core Europe Conference on Cancer Immunotherapy.
In 2017, the 6th Asia Pacific Breast Cancer Summit will once again to bring together international & regional faculty experts in breast cancer to cover surgical, radiation and medical oncology related topics on early and advanced breast cancer management.
An outstanding faculty of speakers from the United States and Europe has committed in this meeting.
The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development.
Leading international and national scientists and physicians will address recent advances in breast cancer research, personalized therapy, and the latest clinical data impacting the treatment of breast cancer. Cutting-edge lectures, panel discussions, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with pioneers as they share their perspectives and personal experiences on the challenges and ongoing controversies in breast cancer.T
European Cancer Genomics research is particularly strong in the Heidelberg area, with three International Cancer Genome Consortium (www.icgc.org) projects being currently pursued with significant participation from Heidelberg institutions, including EMBL. As in our 2015 meeting, a large number of renowned speakers will be invited, with a strong representation of overseas speakers. The atmosphere at the conference will make this an exceptional event with cutting edge science, extensive scientific discussions and ample possibilities for meetings between and after sessions to facilitate in-depth discussions and new collaborations.
Last updated: 23 October 2016